BWA
NAGE

Basecamp Wealth Advisors’s Niagen Bioscience NAGE Stock Holding History

Basecamp Wealth Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373 Sell
117
-155
-57% -$629 ﹤0.01% 1668
2026
Q1 		$1.2K Buy
+272
New +$1.47K ﹤0.01% 1513

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Basecamp Wealth Advisors's NAGE Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Niagen Bioscience (NAGE) stake by 57% in Q2 2026, selling an estimated $629 and leaving 117 shares worth $373. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

Basecamp Wealth Advisors first reported a position in NAGE in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.2K in Q1 2026. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Basecamp Wealth Advisors held 117 shares of Niagen Bioscience worth $373 as of Q2 2026.
  • Basecamp Wealth Advisors sold 155 Niagen Bioscience shares in Q2 2026, an estimated $629.
  • Niagen Bioscience made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1668 holding.
  • Basecamp Wealth Advisors first reported a position in Niagen Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Niagen Bioscience position peaked at $1.2K in Q1 2026.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.